Health
Pioneering Progress: New Mexico’s Path to Better Cancer Outcomes
New Mexico Statewide Cancer Clinical Trials Network reviewed state’s cancer clinical trials and celebrated advances in cancer care at June Scientific Retreat
Last Updated on November 17, 2024 by Daily News Staff

Chandylen Nightingale, PhD, MPH, Wake Forest University, was the keynote speaker at the NMCRA Scientific Retreat
« Stronger Together
For nearly 20 years, the New Mexico Cancer Care Alliance (NMCCA) ensured that New Mexicans in all parts of the state had access to cancer clinical trials. That network of health care organizations has modernized its processes. It also strengthened its focus and mission on delivering clinical trials and clinical research to prevent, detect, and treat cancer and to improve patient outcomes, experiences and access to cancer care using culturally sensitive approaches.
The rebranded organization, now called the New Mexico Cancer Research Alliance (NMCRA), held its first in-person scientific retreat on June 21. Attendees at the event represented The University of New Mexico Comprehensive Cancer Center, Presbyterian Healthcare Services, Lovelace Health System and Memorial Medical Center and the Veteran’s Administration Hospital System.
Summary
- The New Mexico Cancer Care Alliance (NMCCA) has rebranded as the New Mexico Cancer Research Alliance (NMCRA) to strengthen its focus on delivering cancer clinical trials to New Mexicans.
- Through the NMCRA’s unique collaboration, every New Mexican has access to cancer clinical trials.
- Cancer clinical trials test new treatments and new methods of delivering and improving cancer care
A “Gem” to Improve Cancer Care
The NMCRA is an incredible gem for the people of New Mexico,” says Carolyn Muller, MD, FACOG, NMCRA Director. “Clinical research improves the lives of cancer patients by focusing on better ways to prevent, detect and treat cancer and to optimally deliver cancer care.”
Cancer Clinical research is conducted through clinical trials, which test new treatments and new methods of delivering and improving cancer care. Some trials test whether new drugs are more efficacious than the currently used “standard” drugs. Some test new drug combinations.
Other cancer clinical trials test better ways to screen for cancer or lessen symptoms from cancer or cancer treatments. Still other trials test different methods of delivering care to different people, such as individuals from different racial or ethnic communities or those who live in rural or underserved communities.
The United States Food and Drug Administration (FDA) oversees all clinical trials in the US. It ensures that all clinical trials are conducted safely and with the full understanding and consent of those who choose to take part in them. It also ensures that clinical trials are “designed, conducted, analyzed and reported according to federal law and good clinical practice (GCP) regulations.”
The FDA enforces a four-phase process of testing through which new treatments are approved for use. Each phase has its own set of requirements that treatments must meet in order to progress to the next phase.
Professional medical organizations, such as the American Society for Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) create guidelines for cancer related clinical practice based on the strength of scientific evidence that results from clinical trials. These standards reflect the latest scientific research and best-known practices for delivering care.
The current standard treatments and care practices in effect today went through scientifically rigorous clinical trials to become the standards. When new clinical trials show a drug, treatment or method to be more effective than the current standard, the practice of cancer care changes.
Muller says that the results of several practice-changing clinical trials were presented at the most recent American Society for Clinical Oncology (ASCO) national conference. Some New Mexico patients took part in those clinical trials.
“Our patients had an opportunity to benefit from the clinical trial treatments, and they also helped future patients receive better care,” says Muller. “They are true heros!”
“Cancer research is the key to progress in our battle against cancer,” says Dr. Heyoung McBride, MD from Lovelace Cancer Center, Radiation Oncology. “It is only through high quality research that we can advance our understanding of biological processes involved in cancer and improve outcomes for patients and loved ones suffering from cancer,” she says.
Daunting Challenges
New Mexico’s small population is spread over a large area: the state ranks fifth in land mass but 36th in population. Offering clinical trials to people throughout the state thus presents a daunting challenge.
Because of their scientific nature, clinical trials demand more than strict adherence to a detailed plan, called a protocol, that every person on the trial must follow. Trials also require evidence that each person has followed that protocol. Should anyone deviate from the protocol – for example, if someone must come off the protocol because of a new health issue or a serious side effect – a note of that situation must also be recorded and reported, especially for safety purposes.
A cadre of expertly-trained research teams are needed to manage clinical trials. Some of these people are trained to ensure that participants in each clinical trial meet all the criteria for joining that trial. Others explain the protocols to potential participants. And many others enter clinical trial data, manage databases, report results to oversight entities, and track patient responses and side effects.
Few, if any, independent doctor’s offices could manage clinical trials on their own. Even some larger health care organizations in the state would struggle under the vast administrative burden. UNM, as the only NCI designated Comprehensive Cancer Center in NM, serves as the academic hub for the NMCRA. And the NMCRA brings cutting edge clinical trials and clinical research from the National Cancer Institute, lead investigators and other stakeholders to the NMCRA member health systems.
Through the NMCRA’s unique collaboration, UNM’s clinical research expertise is shared with all affiliated cancer treatment providers in the state. The UNM Cancer Center’s Clinical Research Office supports many of the core functions of the NMCRA.
This collaborative effort between the academic and community health systems partners has led to sustained funding support from the National Cancer Institute’s National Community Oncology Research Program (NCORP).
“The NCORP Program delivers state-of-the-art national cooperative group clinical treatment, prevention and screening trials to New Mexico,” Muller says. She also notes that many clinical research leaders in New Mexico across the NMCRA not only serve on the national committees that help to shape the future of these trials but also make sure that New Mexicans can access these trials.
“Health systems in New Mexico value cancer clinical trials,” says Muller.
William Adler, MD, at Memorial Medical Center in Las Cruces, sees the benefits of clinical trials for New Mexicans, He says, “Memorial Cancer Center has made clinical research trials a priority for nearly 15 years. The availability of these national and international studies allows patients to stay at home with their families and still have access to the leading edge of cancer care. The cancer program at Memorial Medical Center has received national recognition for its clinical trial research activities. As the umbrella organization, NMCRA has made cancer clinical research possible in southern New Mexico.”
Malcom Purdy, MD, at Lovelace Cancer Center Medical Oncology agrees. He says, “The Lovelace Cancer Center has participated in clinical trials with the University of New Mexico for close to 40 years. These have included groundbreaking studies which have advanced patient care and cancer treatment, especially in breast cancer. Unlike clinical trials for other conditions, clinical trials for cancer patients take the best of what we know now and add to that care, so all participants receive excellent care. I always tell my patients that participation in a clinical trial gives the best care.
Access for All
As the many affiliates of the NMCRA know, offering the best cancer care isn’t good enough; that care must reach the people who need it.
In addition to the large cancer care providers, smaller oncology practices throughout the state are also NMCRA affiliates. They provide cancer clinical trials to people in some of the most underserved and remote areas in New Mexico.
And the National Cancer Institute (NCI) also recognizes the need to bring cancer care and cancer research to people who have not taken part in clinical trials in the past or who may face significant barriers to joining then now.
Through the NCORP grants, the NCI has created “a national network that brings cancer clinical trials and care delivery studies to people in their own communities.” The UNM Cancer Center is one of the Minority/Underserved NCORP sites, and NCI cancer clinical trials are delivered through the NMCRA
The NCI is also focusing on cancer care delivery. Cancer care delivery research studies how different processes, models, concepts and approaches can improve the quality of cancer care, patient outcomes, and access to care.
Chandylen Nightingale, PhD, MPH, Assistant Professor in the Department of Social Sciences and Health Policy, Division of Public Health Sciences, at Wake Forest University School of Medicine spoke at the recent NMCRA scientific retreat and shared her research and insights and the importance of cancer care delivery research.
“It is imperative for New Mexico’s cancer patients to have access to innovative treatments that will hopefully move cancer care forward,” says Ethan Binder, MD, at Presbyterian Healthcare Services Hematology/Oncology. “The NMRCA is a wonderful collaborative effort that truly tailors cancer research for New Mexicans.”
Some of the NMCRA Member Institutions
The University of New Mexico Comprehensive Cancer Center
The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. Its more than 120 board-certified oncology specialty physicians include cancer surgeons in every specialty (abdominal, thoracic, bone and soft tissue, neurosurgery, genitourinary, gynecology, and head and neck cancers), adult and pediatric hematologists/medical oncologists, gynecologic oncologists, and radiation oncologists. They, along with more than 600 other cancer healthcare professionals (nurses, pharmacists, nutritionists, navigators, psychologists and social workers), provide treatment to 65% of New Mexico’s cancer patients from all across the state and partner with community health systems statewide to provide cancer care closer to home. They treated approximately 14,000 patients in about 100,000 ambulatory clinic visits in addition to in-patient hospitalizations at UNM Hospital. A total of nearly 400 patients participated in cancer clinical trials testing new cancer treatments that include tests of novel cancer prevention strategies and cancer genome sequencing. The more than 100 cancer research scientists affiliated with the UNMCCC were awarded $35.7 million in federal and private grants and contracts for cancer research projects. Since 2015, they have published nearly 1000 manuscripts, and promoting economic development, they filed 136 new patents and launched 10 new biotechnology start-up companies. Finally, the physicians, scientists and staff have provided education and training experiences to more than 500 high school, undergraduate, graduate, and postdoctoral fellowship students in cancer research and cancer health care delivery. Visit www.UNMHealth.org/cancer.
Presbyterian Healthcare Services
Presbyterian Healthcare Services exists to improve the health of patients, members and the communities we serve. Presbyterian is a locally owned, not-for-profit healthcare system of nine hospitals, a statewide health plan and a growing multi-specialty medical group. Founded in New Mexico in 1908, it is the state’s largest private employer with more than 13,000 employees.
Lovelace Health System (Lovelace) recently celebrated its 100th anniversary, marking a century of caring, change and progress while continuously improving the practice of medicine.
Lovelace is comprised of Lovelace Medical Group/New Mexico Heart Institute, Lovelace Women’s Hospital, Lovelace Medical Center, Heart Hospital of New Mexico at Lovelace Medical Center, Lovelace Westside Hospital, Lovelace Regional Hospital and Lovelace UNM Rehabilitation Hospital. Across its six hospitals, 33 health care clinics and seven outpatient therapy clinics, Lovelace has 619 inpatient beds and employs a team of more than 3,450, including over 280 health care providers. Lovelace continues to invest in our community, providing more than $81 million in unfunded care and supporting local nonprofit and community organizations with more than $357,000 in charitable contributions and community support in 2022. From the first and only hospital in New Mexico dedicated to women’s health to the state’s only hospital devoted exclusively to cardiovascular care, Lovelace is a leader in meeting the healthcare needs of this region. To learn more about our state-of-the-art treatment options, innovative health care providers and award-winning quality initiatives, visit lovelace.com.
Memorial Medical Center is a 199-bed full-service acute care hospital located in Las Cruces, New Mexico and serving a five-county region of Southern New Mexico. Our mission is simple: Making Communities Healthier. We are a part of the LifePoint Health family of hospitals, which means we aim to create a place where people choose to come for healthcare, physicians and providers want to practice, and employees want to work. Learn more at mmclc.org.
Source: Michele W. Sequeira, MS, MBA, MWC & University of New Mexico Comprehensive Cancer Center
The science section of our news blog STM Daily News provides readers with captivating and up-to-date information on the latest scientific discoveries, breakthroughs, and innovations across various fields. We offer engaging and accessible content, ensuring that readers with different levels of scientific knowledge can stay informed. Whether it’s exploring advancements in medicine, astronomy, technology, or environmental sciences, our science section strives to shed light on the intriguing world of scientific exploration and its profound impact on our daily lives. From thought-provoking articles to informative interviews with experts in the field, STM Daily News Science offers a harmonious blend of factual reporting, analysis, and exploration, making it a go-to source for science enthusiasts and curious minds alike. https://stmdailynews.com/category/science/
health and wellness
How Clinical Trials Really Work: Understanding the 4 Phases
Understanding how clinical trials work can help demystify the experience, while the research itself helps answer important questions about diseases, treatment options and more. If you, your healthcare team and the study researchers decide an experimental drug trial is right for you, different questions will be answered depending on which phase you participate in.

How Clinical Trials Really Work: Understanding the 4 Phases
(Feature Impact) The idea of participating in a clinical trial can feel overwhelming, especially if you aren’t sure what’s actually involved in the process. Understanding how clinical trials work can help demystify the experience, while the research itself helps answer important questions about diseases, treatment options and more.
According to a study by the Crohn’s & Colitis Foundation, nearly 1 in 100 Americans has inflammatory bowel disease (IBD), a term encompassing a group of conditions that includes Crohn’s disease and ulcerative colitis. These disorders affect the gastrointestinal tract and cause inflammation of the intestines, which can lead to symptoms and sometimes more complicated issues throughout the body. Research into this condition has the potential to change lives, including those of the participants themselves, yet many clinical trials face delays due to lack of enrollment.
“We need more people to get involved in clinical trials, especially those from underrepresented communities, including people of color and older adults, who have some of the highest rates of chronic disease,” said Dr. Ruby Greywoode, a gastroenterologist at Montefiore Medical Center.
Clinical trials can take many forms including medication studies, medical tests, investigating the role of diet in disease management or examining the emotional impact of living with a condition such as IBD. Each trial is typically divided into four phases, which all build on each other but are conducted separately.
If you, your healthcare team and the study researchers decide an experimental drug trial is right for you, different questions will be answered depending on which phase you participate in.
Phase 1: Is the Drug Safe to Use?
The first phase of a clinical trial is the smallest and often conducted among a group of healthy people who don’t have the condition in question. Researchers want to know how the human body reacts to the medication, determine safe dosage ranges and identify potential side effects.
Phase 2: Is the Drug Effective?
Once a drug has been evaluated for overall safety in healthy people, the clinical trial moves on to test the treatment in a slightly larger group of people. Those participating in this phase have the condition for which the new treatment is being developed. For instance, a phase 2 IBD clinical trial might give the drug to 100 people with IBD to see whether it works or causes any short-term side effects. Participants are randomly assigned to different treatment groups, which may involve different dosages or placebos (not active treatment).
Phase 3: Does It Work Better Than Currently Available Treatments?
If the second phase yields positive results, the study expands again to test the new drug against current treatment options. A phase 3 clinical trial lasts longer and involves more participants than the first two phases as researchers try to gain as much information as possible about how the drug affects different kinds of people, whether it’s better than standard treatments or placebos and what side effects may arise over a longer period of time.
At the end of this phase, the company decides whether the trial results are strong enough to submit an application to the FDA, at which point the treatment will be reviewed and potentially approved.
Phase 4: How Does the Drug Work in Real Life?
Research usually doesn’t end when a drug gets approved. Instead, it moves into the fourth phase, where companies monitor the ongoing real-world uses and effects of the medication. This can involve following thousands of patients for several years to gather as much information as possible.
If you’re one of the millions of people living with IBD in the U.S., clinical trials offer hope for a future with more treatments, less pain and healthier lives. That’s why the Crohn’s & Colitis Foundation wants to make clinical trials less mysterious, more accessible and more representative of the real people affected by these conditions.
Talk to your healthcare professional about whether a clinical trial could be right for you and explore IBD research opportunities at CrohnsColitisFoundation.org.
Clinical Trial FAQs
What is the average length of a clinical trial?
The length of clinical trials vary. They can be as short as a month or as long as one year or more. Generally, the earlier the phase, the shorter the trial period. How do you identify clinical trials you’re eligible for?
Eligibility criteria differ from study to study and may include factors like age, gender, medical history and current health status. For instance, some IBD studies may be looking for patients with mild symptoms, while others want to test treatments for moderate to severe disease. If you’re interested in a particular trial, review the criteria to see if you qualify to participate.
Is it free to participate in clinical trials?
Most clinical trials are federally or privately funded, so there is typically no cost to the participant. Associated costs like travel, time off work and childcare may or may not be covered by the trial sponsor, so it’s worth confirming these details before committing.
What if you enroll in a trial then change your mind?
You’re free to withdraw from a clinical trial at any time. If you drop out during testing, you may be asked to come in for follow-up visits to ensure your safety.
If the treatment helps, can you keep using it after the trial ends?
It depends. Some trial sponsors allow participants to continue receiving the drug voluntarily, while others only make it available after it’s been approved by the FDA.
How can you get involved in clinical trials?
Talk to your doctor about whether participating in a clinical trial may be right for you. If you’re interested in IBD clinical trials, you and your doctor can search for opportunities at crohnscolitisfoundation.org/clinical-trials-community.
“Clinical trials give patients a real way to shape the future of treatment,” Greywoode said. “It’s not just about their own care; it can help others, too. Talking openly with your doctor can help you feel more confident about getting involved.”
Photos courtesy of Shutterstock
SOURCE:
Health
Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it
Decades of public health campaigns have reinforced the connection between smoking and lung cancer, helping people understand that their choices can influence their health. Despite radon being the second-leading cause of lung cancer, many have never tested their home for it.

Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it
(Sheeka Sanahori) Avoid tobacco products. Eat a healthy diet. Get recommended cancer screenings. Most U.S. adults recognize these behaviors as ways to lower their cancer risk or catch cancer early. Decades of public health campaigns have reinforced the connection between smoking and lung cancer, helping people understand that their choices can influence their health.
But U.S. adults are far less likely to recognize a risk factor they can’t control through daily habits. Radon – an odorless, invisible gas that forms naturally in the ground – is the second leading cause of lung cancer, but new research from the Prevent Cancer Foundation finds that 8 in 10 U.S. adults have never tested their home for radon. The findings are based on the Foundation’s annual Early Detection Survey of more than 7,000 U.S. adults, conducted in January 2026.
With recent high-profile lung cancer cases, such as the October diagnosis of Pope Leo XIV, who is not known to have a history of smoking cigarettes, more people are paying attention to other risk factors for lung cancer, especially for people who have never smoked.
Testing for radon is last on the list
When asked about preventive behaviors, 77.5% say avoiding tobacco lowers their cancer risk. Three out of four say eating a healthy diet and getting routine cancer screenings make a difference, too. More than half also named regular exercise, limiting alcohol and protecting themselves from harmful UV rays.
Testing their home for radon ranked last on the list of preventive behaviors, with only 28% listing it as a way to reduce their cancer risk.
Most homes go untested in every region
Radon hasn’t reached the same level of public awareness as tobacco use, diet and exercise. U.S. adults appear to overlook an environmental risk that could be inside their own homes. Eighty percent of U.S. adults report never having their homes tested for radon, and only 12% have tested within the last five years. The U.S. Environmental Protection Agency (EPA) recommends testing every two years.
In the Northeast, about 7 in 10 people (72%) have never tested their home for radon. That percentage increases for the Midwest (79%), West (82%) and South (83%). Unlike cigarettes, radon does not produce smoke and is odorless, so a test is the only way to detect its presence.
What it takes to find out
Radon can enter homes through the ground when uranium underneath decays. Once it’s inside, it gets trapped. People can live with high radon levels without knowing it, in older homes and new construction alike. Breaking ground on undisturbed land during construction can release more radon.
Renters can either test themselves or ask their landlord whether the home has been tested and request the results. Landlord requirements vary by state.
Test kits are inexpensive and available online and at home improvement stores. The EPA recommends taking action to reduce radon levels at 4 picocuries per liter (pCi/L) or higher, and notes that levels below that may still carry risk. If levels are high, a mitigation system can bring them down.
Beyond radon, the EPA and other health authorities cite avoiding tobacco and secondhand smoke as the most significant steps people can take to lower lung cancer risk, along with following screening guidelines based on personal risk factors.
Methodology
The Prevent Cancer Foundation commissioned Atomik Research to conduct the Foundation’s fourth annual Early Detection Survey of U.S. adults. The study consists of an online survey questionnaire, which includes several repeated measures from a previous year’s questionnaire and a primary data set gathered from a sample of 7,510 adults located throughout the United States. The sample consists of adults 21 years of age or older, and researchers implemented several demographic-based quotas in order to achieve sample characteristics similar to the overall U.S. population of adults 21 and older.
Researchers controlled for demographic variables such as biological sex, age group classification, race/ethnicity, parental status, geographic region, employment status and community classifications (e.g., urban or rural classification).
The margin of error of the overall sample is +/-1 percentage point with a confidence level of 95%. Fieldwork took place between Jan. 10 and Jan. 30, 2026. Atomik Research is an independent market research agency.
Percentages may not add up to 100% due to computer rounding, and/or the acceptance of multiple responses.
Photo courtesy of Shutterstock (family playing)
SOURCE:
Prevent Cancer Foundation
Women's Health
Menopause changes your mouth. Most women have no idea.
Menopause changes your mouth: Many women are familiar with the most talked-about symptoms of menopause – hot flashes, disrupted sleep, brain fog and mood swings. Far fewer know that dry mouth and sensitive teeth belong on that list too.

Menopause changes your mouth. Most women have no idea.
(Sheeka Sanahori) Many women are familiar with the most talked-about symptoms of menopause – hot flashes, disrupted sleep, brain fog and mood swings. Far fewer know that dry mouth and sensitive teeth belong on that list too.
There’s a name for it: menopause mouth. According to survey data from Delta Dental Insurance Company, 83% of women 40 and older in menopause aren’t aware of any of its symptoms.
What menopause mouth feels like
Forty percent say they have noticed an increase in dry mouth. Another 27% have noticed more tooth sensitivity in recent months, and 26% say things taste different than they used to. You tell yourself it’s something else. You’re not drinking enough water; you’ve been brushing too hard. Menopause isn’t the first thing that comes to mind.
It adds up. Forty-five percent say oral symptoms associated with menopause, such as tooth pain, dry mouth or gum inflammation, take a toll on their confidence, mood or mental health.
Menopause affects the whole body, mentally and physically. So why is the mouth left out?
Even after learning about this connection, 30% of women say they can’t find information about menopause-related oral health concerns. It isn’t that no one is willing to discuss it.
What makes the conversation hard to start
Three-quarters of dentists say they are comfortable discussing menopause with patients. They just want to know who they’re talking to. Most say they would want more patient history, or to know a patient was in menopause, before raising the subject. Forty-five percent say they would not bring up how menopause affects oral health unless a patient asked.
Dentists also believe that patients are already informed. Ninety-four percent say their patients are at least somewhat aware that menopause can affect oral health. So a patient says nothing about her dry mouth, because it doesn’t seem like a dental problem. The dentist doesn’t bring it up either, assuming someone already has.
Women are asking for the information
Nearly nine in 10 women say it would help to receive specific instructions during dental visits about managing oral health during menopause. And 69% say they would be more likely to book an appointment if a primary care provider or OB-GYN had told them menopause affects oral health.
No matter who brings it up, the conversation is one worth having. Hormonal changes during menopause can increase the risk of tooth loss or tooth decay, gum disease, receding gumline or loss of jawbone density. Discussing new oral symptoms with a dentist can help women identify potential problems and address them early.
How to start the conversation with your dentist
Your dentist probably doesn’t know you’re in menopause. Start there.
Questions worth asking:
- “Could the changes I’m noticing be related to menopause?”
- “I haven’t had a cavity in 30 years, and now I have two. Could that be tied to hormonal changes?”
- “What can I do about dry mouth?”
- “Are there symptoms I should watch for?”
- “Should I adjust my oral care routine?”
Any one of these questions can get the conversation started.
Methodology
Delta Dental Insurance Company commissioned Atomik Research to conduct two online surveys between June 25 and July 2, 2025.
The first surveyed 200 dentists throughout the United States. The margin of error is +/- 7 percentage points with a 95% confidence level.
The second surveyed 1,511 women ages 40 or older throughout the United States. To qualify, participants had to indicate they are in perimenopause, menopause or post-menopause. Those who were not sure which stage they were in, or who indicated they were not yet in one of the three stages, were excused from participation. The margin of error is +/- 3 percentage points with a 95% confidence level
Atomik Research, part of 4media group, is an independent market research agency.
Photo courtesy of Shutterstock
SOURCE:
Delta Dental Insurance Company
